Breaking News

NAFDAC Approves Chloroquine for Coronavirus Clinical Trials



The National Agency for Food and Drug Administration and Control (NAFDAC) has just approved the manufacture of Chloroquine for clinical trials in order to find a permanent cure for coronavirus which has traumatized countries around the world. 
NAFDAC's Director-General, Mojisola Adeyeye who made the announcement at the Lagos headquarters of the agency stated that NAFDAC is not approving Chloroquine for the treatment of  COVID-19 but for clinical trials to find treatment for the virus.

She said;  
“In the case of Chloroquine, it has been established in the writings and with clinical research which is ongoing, that Chloroquine is superior to the Placebo. NAFDAC is not approving Chloroquine as a product to be used for Coronavirus because there is no submission to us for registration but because it is under clinical trials, NAFDAC approves medicines meant for clinical trials. Therefore the medicine is being approved for just the clinical trials. Right now, we have asked one company to make a batch of Chloroquine for the purpose of clinical trial."

She called on experts and researchers that are concerned in caring out a clinical trial on Chloroquine to approach permitted outlets, she also urged Nigerians not to use Chloroquine as an anti-malaria drug. 

She added that: 
“Chloroquine is banned for use as anti-malaria."

No comments